News

The amyotrophic lateral sclerosis (ALS) drug Relyvrio has been pulled from US and Canadian markets by its maker, Amylyx Pharmaceuticals, after topline trial data showed it worked no better than a placebo.

Imagine switching on a light and being able to understand and control the inner dynamics of a cell. By shining lights of different colors on replicates of cells, researchers altered the interactions between cellular elements.

Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant bacteria, and have shown that it cures bloodstream infections in mice.

A University of Oklahoma study about a “black box warning” for the asthma drug Singulair continues to influence a national conversation about the medication and its reported neuropsychiatric side effects in children and adolescents.

The active ingredient in many drugs is what’s known as a small molecule: bigger than water, much smaller than an antibody and mainly made of carbon. Scripps scientists have uncovered a potential cost-effective way to produce these tricky motifs.

Fecal microbiota transplantation improves motor symptoms in Parkinson’s disease patients after 12 months. That's according to data from the GUT-PARFECT trial that recruited 46 Parkinson's disease patient.

Chemists have created a new collection of molecular compounds and begun testing them as potential leads in the search for new drugs. Among these molecules, they found several that show promise for development as antibiotics and cancer therapies.

Empa researchers have succeeded in 3D printing the natural material into complex shapes that could one day serve as precision insulation in microelectronics or as personalized medical implants.

Mayo Clinic scientists have developed an immunotherapy strategy that utilizes CAR-MSCs. The approach shows potential in targeting inflammatory disease sites more precisely and improving immunosuppression and healing outcomes.

Results from a Phase 2 clinical trial suggest that lixisenatide – a drug used to treat type 2 diabetes – may also slow the progression of Parkinson’s disease symptoms.